genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Company profile
Ticker
GNPX
Exchange
Website
CEO
J. Rodney Varner
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GNPX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
17 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
424B5
Prospectus supplement for primary offering
20 Mar 24
8-K
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
20 Mar 24
8-K
Other Events
6 Mar 24
8-K
Other Events
26 Feb 24
8-K
Departure of Directors or Certain Officers
5 Feb 24
8-K
Departure of Directors or Certain Officers
2 Feb 24
8-K
Material Modifications to Rights of Security Holders
31 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
Latest ownership filings
4
Mark Stanley Berger
21 Feb 24
4
John Rodney Varner
21 Feb 24
4
Ryan M. Confer
21 Feb 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G
CVI Investments, Inc.
24 Jul 23
4
Toscano Jose Antonio Moreno
29 Jun 23
4
BRENT M LONGNECKER
29 Jun 23
4
William R Jr. Wilson
29 Jun 23
4
John Rodney Varner
24 Apr 23
4
CATHERINE M VACZY
24 Apr 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.71 mm | 11.71 mm | 11.71 mm | 11.71 mm | 11.71 mm | 11.71 mm |
Cash burn (monthly) | (no burn) | 1.15 mm | 2.60 mm | 2.64 mm | 1.58 mm | 2.04 mm |
Cash used (since last report) | n/a | 7.63 mm | 17.21 mm | 17.50 mm | 10.47 mm | 13.53 mm |
Cash remaining | n/a | 4.08 mm | -5.50 mm | -5.79 mm | 1.24 mm | -1.82 mm |
Runway (months of cash) | n/a | 3.5 | -2.1 | -2.2 | 0.8 | -0.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 10 |
Closed positions | 9 |
Increased positions | 4 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 3.60 bn |
Total shares | 3.83 mm |
Total puts | 0.00 |
Total calls | 22.10 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.83 mm | $1.73 bn |
BLK Blackrock | 456.36 k | $432.90 mm |
Geode Capital Management | 447.21 k | $424.22 mm |
STT State Street | 172.44 k | $163.58 mm |
Rockefeller Capital Management | 150.00 k | $142.29 mm |
Cypress Capital | 100.00 k | $94.86 mm |
IHT Wealth Management | 82.37 k | $78.14 mm |
NTRS Northern Trust | 81.86 k | $77.65 mm |
SAMG Silvercrest Asset Management | 56.00 k | $53.12 mm |
Verus Capital Partners | 51.50 k | $48.86 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Jun 23 | William R Jr. Wilson | Common Stock | Grant | Acquire A | No | No | 0 | 123,795 | 0.00 | 123,795 |
27 Jun 23 | Brent M Longnecker | Common Stock | Grant | Acquire A | No | No | 0 | 123,795 | 0.00 | 138,795 |
27 Jun 23 | Toscano Jose Antonio Moreno | Common Stock | Grant | Acquire A | No | No | 0 | 123,795 | 0.00 | 123,795 |
21 Apr 23 | Catherine M Vaczy | Common Stock | Buy | Acquire P | No | No | 1.0739 | 20,000 | 21.48 k | 265,000 |
21 Apr 23 | Varner John Rodney | Common Stock | Buy | Acquire P | Yes | No | 1.055 | 19,000 | 20.05 k | 20,800 |
News
Genprex Earlier Reported Preclinical Data For Reqorsa Immunogene Therapy And NPRL2 Gene Therapy For Lung Cancer
9 Apr 24
HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
4 Apr 24
Genprex Expands Clinical Trial Sites For Acclaim-3 Clinical Study Of Reqorsa Therapy In Combination With Tecentriq For Small Cell Lung Cancer
3 Apr 24
HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
3 Apr 24
Genprex Publishes Preclinical Data With NPRL2 Gene Therapy Using Oncoprex Delivery System
2 Apr 24
Press releases
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
9 Apr 24
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
3 Apr 24
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
2 Apr 24
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
22 Mar 24
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19 Mar 24